Company Description

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care.

Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.

The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.

BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BriaCell Therapeutics Corp.

Country	Canada
Founded	2014
Industry	Biotechnology
Sector	Healthcare
Employees	16
CEO	William Williams

Contact Details

Address: Bellevue Centre, Suite 300 West Vancouver, BC V7T 2X1 Canada
Phone	604-921-1810
Website	briacell.com

Stock Details

Ticker Symbol	BCTX
Exchange	NASDAQ
Fiscal Year	August - July
Reporting Currency	USD
CIK Code	0001610820
CUSIP Number	10778Y302
ISIN Number	CA1079301091
SIC Code	2834

Key Executives

Name	Position
Dr. William V. Williams M.D.	Chief Executive Officer, President and Director
Gadi Levin B.Com., C.A., CPA, M.B.A.	Chief Financial Officer and Corporate Secretary
Dr. Miguel A. Lopez-Lago Ph.D.	Chief Scientific Officer
Dr. Giuseppe Del Priore M.D., M.P.H., MPH	Chief Medical Officer
Dr. Charles Louis Wiseman FACP, M.D.	Founder, Principal Research Advisor and Member of Scientific Advisory Board

Latest SEC Filings

Date	Type	Title
Nov 1, 2024	8-K	Current Report
Oct 29, 2024	10-K	Annual Report
Oct 2, 2024	8-K	Current Report
Oct 2, 2024	424B5	Filing
Oct 1, 2024	8-K	Current Report
Sep 16, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Sep 12, 2024	8-K	Current Report
Sep 12, 2024	424B5	Filing
Sep 11, 2024	8-K	Current Report
Aug 23, 2024	8-K	Current Report

View All SEC Filings